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ABSTRACT
Purpose. To evaluate the effects of epoetin alfa on pa-
tient-reported outcomes (PROs) in patients with breast
cancer receiving myelotoxic chemotherapy.
MaterialsandMethods.Womenwithhemoglobincon-
centrations <12.0 g/dl and an Eastern Cooperative On-
cology Group performance status (ECOG PS) score of
0–3 were randomized 1:1 to receive epoetin alfa (10,000
IU 3 times weekly) or best standard care (BSC) during
chemotherapy. The primary endpoint was the change
from baseline in the total anemia subscale assessed by
the Functional Assessment of Cancer Therapy–Anemia
(FACT-An) questionnaire after 12 weeks of treatment.
The fatigue and nonfatigue subscales from the FACT-
An, the Cancer Linear Analog Scale (CLAS), hemoglo-
bin changes, ECOG PS score, tumor response, overall
survival, and safety also were evaluated.
Results. Of 223 patients randomized, 216 constituted
the modified intent-to-treat population. Percentage
changes in the total anemia subscale of the FACT-An
were significantly different between epoetin alfa treat-
ment (14.2%) and BSC (0.5%; p  .002), favoring
epoetin alfa; so were changes in the FACT-An fatigue
subscale (epoetin alfa, 17.5%; BSC, 0.9%; p  .003)
and nonfatigue subscale (epoetin alfa, 8.8%; BSC,
0.2%; p  .008). Similar results were observed with the
CLAS. Hemoglobin concentrations >12 g/dl were more
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(27.6%). Tumor response, ECOG PS score, 12-month
survival rate, and the incidence of serious treatment-
emergent adverse events were similar between groups.
Conclusion. Early intervention with epoetin alfa was
well tolerated and improved anemia-related PROs in
patientswithbreastcancerreceivingmyelotoxicchemo-
therapy. The Oncologist 2010;15:935–943
INTRODUCTION
Breastcancerisoneofthemostcommonlife-threatening
malignancies in women. Survival rates generally have
improvedasaconsequenceofincreaseddetectionofear-
ly-stage disease and the introduction of more effective
therapeutic regimens [1]. Maintenance of general health
and well-being during and after treatment also is essen-
tial, and supportive care has become an important com-
ponent of overall disease management. Anemia is a
frequent complication of cancer that results from the dis-
ease and/or cytotoxic treatment regimens. If untreated/
not managed properly, anemia can lead to physical and
functional impairment, with fatigue and exhaustion be-
ingthemostcommonsymptoms.Resultsofthe2004Eu-
ropean Cancer Anemia Survey showed that most cancer
patients with anemia (hemoglobin concentration 12.0
g/dl), including those with breast cancer, did not receive
treatment for their anemia [2]. A more recent epidemio-
logic study (the Anaemia Cancer Treatment study) re-
viewed data from 2,807 patients with cancer-related
anemia (hemoglobin concentration 11 g/dl) in 16 Eu-
ropean countries [3]. Results showed that treatment pat-
terns followed accepted guidelines, and that judicious
use of erythropoiesis-stimulating agents (ESAs) gener-
ally was safe and effective.
The therapeutic benefit of correcting chemotherapy-
induced anemia through the use of epoetin alfa in pa-
tients with cancer has been well documented in double-
blind, placebo-controlled, randomized studies [4–6] and
innonrandomized,community-based,open-labelstudies
[7–9]. Results from those studies consistently demon-
strate that epoetin alfa significantly increases hemoglo-
bin concentrations or hematocrit and decreases the
incidence of blood transfusions when treatment is initi-
ated at hemoglobin concentrations up to 11.5 g/dl, and
that successful treatment of anemia is correlated with
measurable and clinically beneficial increases in energy
level and functional status. The current study was under-
taken in women with breast cancer receiving myelotoxic
chemotherapy who had hemoglobin concentrations
12.0 g/dl for the purpose of evaluating the effects of
treatment with epoetin alfa on anemia-related patient-
reported outcomes (PROs).
MATERIALS AND METHODS
Study Population and Design
This was a phase IIIb, randomized, open-label, multicenter
study conducted in six European countries. It consisted of a
pretreatmentvisit,fourvisitsduringtreatmentatweek4–6,
week 9, week 12, and up to week 28, depending on dura-
tion of treatment, and two follow-up visits at 6 and 12
months.Theprotocolwasapprovedbytheindependenteth-
ics committee at each center, and the study was conducted
in accordance with the International Conference on Har-
monisation Harmonised Tripartite Guidelines for Good
Clinical Practice and with the Declaration of Helsinki,
South Africa amendment of 1996. All patients gave written
informed consent prior to study entry.
Women aged 18 years with a confirmed diagnosis of
breast cancer were included in the study. Patients were
mildly anemic (hemoglobin concentration 12.0 g/dl) and
were receiving myelotoxic chemotherapy for a planned
minimum of 12 weeks. The most common chemotherapy
agents used were epirubicin, fluorouracil, and cyclophos-
phamide. Patients also had an Eastern Cooperative Oncol-
ogy Group performance status (ECOG PS) score of 0–3, a
life expectancy 6 months, and adequate renal, hepatic,
and hematologic function (not the result of transfusion).
Exclusion criteria included the following: uncontrolled
hypertension; dysfunction of any organ system not attribut-
able to the malignancy or chemotherapy; active second pri-
mary malignancy within the last 3 years (other than basal
cell carcinoma or cervical cancer in situ); symptomatic or
untreated brain metastases; pregnancy or lactation; hyper-
sensitivity to epoetin alfa; anemia caused by factors other
than cancer or its therapy; untreated iron, folic acid, or vi-
tamin B12 deficiency; acute major illness within 7 days of
study entry; blood transfusion within 14 days of study en-
try; major infection within 1 month of study entry; treat-
ment with ESAs within 4 weeks of study entry; and
participation in any other anemia-related investigational
drug trial within 30 days of randomization.
Eligible patients were randomized 1:1 to receive epoetin
alfa (Eprex; Ortho Biotech Europe, a division of Janssen-
Cilag, Ltd, High Wycombe, U.K.) or best standard care
(BSC).Epoetinalfawasinitiatedat10,000IU(5,000IUifthe
patient was 45 kg) s.c. three times weekly for 4 weeks. He-
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untiltheincreaseinhemoglobinwasstable,afterwhichhemo-
globin was monitored at least monthly until study completion
(up to week 28). A gradual increase in hemoglobin concentra-
tionofupto2g/dlpermonthwasrecommended.Doseadjust-
ments were made if the hemoglobin concentration had not
increased by 1.0 g/dl above baseline after the first cycle of a
4-week cycle of chemotherapy or the first two cycles of a
3-weekcycleofchemotherapy,withtheintenttomaintainhe-
moglobinconcentrationsintherangeof12.5–14g/dl.Epoetin
alfa was stopped in cases of a rise in hemoglobin 2 g/dl per
month or a hemoglobin concentration 14 g/dl. Patients con-
tinued on epoetin alfa until 4 weeks after the end of their last
chemotherapy cycle.
Evaluation of Efficacy and Safety
The primary efficacy endpoint was the change from base-
line in the total anemia subscale from the Functional As-
sessment of Cancer Therapy–Anemia (FACT-An) after 12
weeks of treatment. The FACT-An questionnaire includes
20 items, of which 13 are fatigue-associated items and
seven are non–fatigue-related items. The Cancer Linear
Analog Scale (CLAS) was used subsequently to further as-
sessPROs.TheCLASconsistsofthreelinearanalogscales
that measure energy, ability to do daily activities, and over-
all quality of life. Each patient was to complete the ques-
tionnaires at the pretreatment visit, as well as after 4–6
weeks, after 9 weeks, after 12 weeks, and at study com-
pletion (up to week 28). The protocol instructed that sub-
jects should be unaware of any hematology results prior to
completing the questionnaires. After completion of the
FACT-An questionnaire, patients were asked to indicate
which item of the questionnaire was of greatest importance
to them and therefore that which would be most desirable
for the treatment to improve.
Secondary endpoints included hematologic response;
scores on the fatigue and nonfatigue subscales of the
FACT-An; scores for CLAS energy, ability to do daily ac-
tivities, and overall quality of life; ECOG PS score; tumor
response to chemotherapy; and 6-month and 12-month
overall survival rates. The number of patients transfused
since the previous visit was assessed for each group at each
visit, and the proportion of patients transfused at least once
duringthetreatmentperiodalsowasdetermined.Tumorre-
sponse was assessed by the investigator at the study com-
pletion visit (up to week 28). Survival analyses were
performed using all long-term follow-up data.
Safety was evaluated by monitoring adverse events
(AEs), which were recorded regardless of their relationship
to study drug and were rated as mild, moderate, or severe.
Hematologic and iron parameters and vital signs also were
evaluated.
Statistical Analysis
Thetargetenrollmentwas400women.Thestudywaspow-
ered (with 80% power) to detect a 3.65 difference between
epoetinalfaandBSCintermsoftheFACT-Antotalanemia
subscale score change from baseline to week 12, assuming
a common standard deviation (SD) of 12. However, slow
and declining enrollment caused the study to be stopped af-
ter 223 patients were enrolled. Assuming two-sided tests of
statistical significance and a type I error rate of 5%, the
sample size was estimated retrospectively to yield 97%
power to detect the specified clinically relevant difference
of 7.4 [10] in the FACT-An total anemia subscale score,
frombaselinetoweek12,betweentheepoetinalfaandBSC
treatment groups, assuming an SD of 14.1.
Thesafetypopulationwasdefinedasallrandomizedpa-
tients who received chemotherapy, the modified intention-
to-treat (mITT) population was defined as all randomized
patients who received chemotherapy and were treated with
at least a single dose of epoetin alfa (for the epoetin alfa
group) and had at least a single postbaseline assessment of
the primary variable, and the per-protocol (PP) population
was defined as all patients from the mITT population with
no major protocol violations. The mITT analysis was re-
garded as the primary analysis. Survival analyses were
based on the all-patients-randomized (APR) population.
Statistical analyses were performed with SAS (SAS In-
stitute, Cary, NC), version 8.1. FACT-An scores and labo-
ratory parameters, including hemoglobin concentration,
hematocrit, reticulocyte count, and transferrin measure-
ment, were compared by one-way analysis of variance
(ANOVA) or the Wilcoxon rank sum test. Changes in he-
moglobin concentrations were analyzed using analysis of
covariance.TumorstagewascomparedusingtheWilcoxon
rank sum test; Pearson’s exact test was used to compare
metastaticdisease,previoussurgery,typeofchemotherapy,
further treatment at follow-up, and blood transfusions dur-
ing the treatment period. Survival distributions were esti-
mated by Kaplan–Meier curves and were compared by log-
rank tests. Because the FACT-An data were skewed at the
baseline, the nonparametric Wilcoxon rank sum test was
usedinparallelwithaone-wayANOVA.ChangesinPROs
between baseline and each monthly visit were analyzed.
RESULTS
Demographic and Baseline Characteristics
FromJanuary2000toJuly2002,223patientswereenrolled
in this study (Fig. 1). Demographic and baseline character-
937 Pronzato, Cortesi, van der Rijt et al.
www.TheOncologist.comistics of the mITT population (Table 1) were well balanced
between the two groups. The most common staging was
stage IV (47.7% of patients) disease (Table 2). The mean
( SD) time on study was 17.2 ( 6.7) weeks overall and
was similar between groups.
FACT-An and CLAS Changes
TheFACT-Anquestionnairewascompletedby98.1%(212
of 216) of patients at baseline and by 98.0% (144 of 147) of
patients at week 12. As is shown in Figure 2A, the percent-
age change from baseline in the mean score on the
FACT-Antotalanemiasubscaleandonthefatiguesubscale
after 12 weeks of epoetin alfa treatment were significantly
different (p  .002 and p  .003, respectively) from those
for the BSC group. Even on the FACT-An nonfatigue sub-
scale, which mainly evaluates subjective signs and symp-
toms of anemia, the change from baseline was significantly
better in the epoetin alfa group (p  .008). Differences in
the two groups were marked more by improvement in the
epoetin alfa group than by deterioration in the BSC group.
Changes from baseline to study end (up to week 28) also
were significantly better for the epoetin alfa group for the
FACT-An total anemia subscale (p  .001, data not
shown).
Figure2BshowsresultsfromtheCLASassessment.All
three variables (energy, ability to do daily activities, and
overall quality of life) were significantly (p  .007) better
thanatbaselineintheepoetinalfagroupcomparedwiththe
BSC group after 12 weeks of treatment. In addition, be-
tween-group differences for all three CLAS change scores
frombaselinetostudyendalsowerestatisticallysignificant
(p  .001), favoring epoetin alfa (data not shown).
Hemoglobin Response
Figure 3 illustrates the change in hemoglobin over time for
the mITT population (similar results were seen in the PP
Figure 1. Patient disposition (mITT population).
Abbreviations: BSC, best standard care; mITT, modified
intention-to-treat; PP, per protocol.
Table 1. Baseline demographic and clinical
characteristics (mITT population)
Characteristic
Epoetin alfa
(n  107)
Best standard
care (n  109)
Age, yrs
Mean  SD 53.3  10.3 54.3  11.6
Range 29–76 27–77
Mean hemoglobin, g/dl 10.6 10.8
Prior cancer surgery, % 90.7 89.0
FACT-An total anemia
subscale score
50.4
a 54.3
ECOG PS score, %
0 59.8 67.9
1 32.7 28.4
2 7.5 3.7
aP  .060 (indicates between-group difference; higher
score  more favorable).
Abbreviations: ECOG PS, Eastern Cooperative Oncology
Group performance status; FACT-An, Functional
Assessment of Cancer Therapy–Anemia; mITT, modified
intention-to-treat; SD, standard deviation.
Table 2. Clinical stage and metastatic disease
n of patients (%) in treatment group
Epoetin alfa
(n  107)
Best standard
care (n  109)
n (%) n (%)
Clinical stage
I 13 (12.1%) 17 (15.6%)
II 33 (30.8%) 31 (28.4%)
III 10 (9.3%) 13 (11.9%)
IV 51 (47.7%) 48 (44.0%)
Metastases
Unknown 1 (0.9%) 0 –
None 51 (47.7%) 63 (57.8%)
Abdominal 4 (3.7%) 5 (4.6%)
Brain 4 (3.7%) 0 –
Bone 36 (33.6%) 29 (26.6%)
Liver 21 (19.6%) 21 (19.3%)
Lung 17 (15.9%) 11 (10.1%)
Lymphatic 13 (12.1%) 15 (13.8%)
Skin 5 (4.7%) 6 (5.5%)
Other 12 (11.2%) 9 (8.3%)
938 Epoetin Alfa Improves Anemia-Related PROs in Breast Cancerpopulation). In the epoetin alfa group, the mean hemoglo-
bin concentration increased from a baseline of 10.6 g/dl to
12.3 g/dl at the week 12 and week 28 assessments, whereas
in the BSC group, it changed from 10.8 g/dl to 11.2 g/dl
(p.001,between-groupdifference).Hemoglobinandhe-
matocritlevelswerethehighestwithin4–6weeksafterini-
tiation of epoetin alfa therapy and remained stable during
the rest of the study. In the mITT population, a higher per-
centage of patients in the epoetin alfa group achieved a he-
moglobinlevel12g/dlduringthestudyperiod,compared
with the BSC group at all evaluation times. At week 12,
62% of patients who received epoetin alfa therapy had
achieved a hemoglobin level 12 g/dl, versus 28% in the
BSCgroup.Nocorrelationbetweenstageofdiseaseandhe-
matologic response was noted (data not shown).
ECOG PS
In the mITT population, the distributions of patients by
ECOG PS score at baseline were similar in the two treat-
ment groups (Table 1). Although no statistically significant
differences between the groups were noted at the 12-week
visit or at the up-to-28-week visit, in the follow-up period,
the number of subjects with an ECOG PS score 2 was
higher in the epoetin alfa group.
Assessment of Tumor Response
Tumor response was assessed at the end of the study (up to
week 28). Among patients in whom a tumor response was
recorded (65 patients in the epoetin alfa group and 56 pa-
tients in the BSC group), no differences were found be-
tween the treatment groups.
Overall Survival
Patients were followed for 1 year after their last study assess-
ment.IntheAPRpopulation,43patientsdiedduringthetreat-
ment and follow-up periods: 23 (20.9%) in the epoetin alfa
group and 20 (17.7%) in the BSC group, with no statistically
significant difference in survival noted between the groups
(Fig. 4). The hazard ratio and 95% confidence interval (CI)
were 1.054 and 0.578–1.919, respectively, with a p-value of
.86. Similar results were seen in the mITT population.
Among all baseline prognostic factors for survival, two
factors—cancer diagnostic clinical stage and age (50
years versus 50 years)—appear to be significant predic-
tors for survival, irrespective of treatment allocation (Table
3). More specifically, stage IV patients had a statistically
significant higher mortality risk than stage I–III patients,
and elderly patients (defined as age 50 years) had a sta-
tistically significant higher mortality risk than younger pa-
tients (Table 4). However, these two factors were well
balanced between the two treatment groups.
Transfusion Requirements
Overall, 16.5% (18 of 109) of patients in the BSC group re-
ceived at least one transfusion during the treatment period,
compared with 7.5% (8 of 107) of patients in the epoetin
alfa group (p  .059). A statistically significant difference
between the treatment groups in the number of transfusions
wasobservedattheendofthestudy;significantlyfewerpa-
tients in the epoetin alfa group than in the BSC group had
required transfusions (3.0% versus 10.1%; p  .048).
Safety
Epoetin alfa was well tolerated. The mean area under the
concentration–time curve for epoetin alfa was 26,634 IU
(range, 4,534.9–70,000 IU). The two treatment groups
were similar in the nature of treatment-emergent AEs re-
Figure 2. Comparing patient-reported outcomes between
epoetin alfa treatment and best standard care. (A): Percent
change in mean FACT-An subscale scores between baseline
and week 12 (mITT population). (B): Percent change in mean
CLAS score between baseline and week 12 (mITT popula-
tion).
Abbreviations: CLAS, Cancer Linear Analog Scale;
FACT-An, Functional Assessment of Cancer Therapy–Ane-
mia; mITT, modified intention-to-treat.
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group of gastric/duodenal and bone/joint disorders, and
more reports in the BSC group of small/large bowel and
mucous membrane disorders. Rates of treatment-emergent
venous thrombosis were similar in the two groups.
Eighteen patients (16.5%) in the epoetin alfa group re-
ported serious AEs, compared with 16 patients (14.4%) in the
BSC group. Serious thrombovascular events occurred in four
patientsintheepoetinalfagroupandinonepatientintheBSC
group.
DISCUSSION
In this prospective, randomized trial, we evaluated the
impactofearlierinterventionwithepoetinalfacompared
withBSCinpatientswithbreastcancerreceivingmyelo-
toxic chemotherapy. The primary endpoint was change
from baseline in the total anemia subscale of the FACT-
An. Patients in the epoetin alfa group showed a signifi-
cant improvement over baseline values during the course
of chemotherapy, whereas patients in the BSC group did
not. Changes in FACT-An total anemia, fatigue, and
nonfatigue subscales were highly significantly different
between the two groups and favored epoetin alfa treat-
ment. These observations were supported by the CLAS
results. In addition, 60% of the patients in the epoetin
alfa group achieved a hemoglobin concentration 12
g/dl after 12 weeks of treatment, compared with 28% of
patients in the BSC group.
Figure 3. Hemoglobin change (mean) over time during the treatment phase (mITT population).
Abbreviation: mITT, modified intention-to-treat.
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Figure 4. Overall survival of patients with breast cancer receiving myelotoxic chemotherapy (APR population; n  223).
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cent trial of early intervention with epoetin alfa therapy in
patients with breast cancer. In that study, treatment with
epoetin alfa (40,000 IU once weekly for at least 12 weeks)
maintained or improved hemoglobin concentrations and
PROs, whereas decreases in hemoglobin concentrations
and declines in PROs were observed in patients who re-
ceived placebo [11].
Epoetin alfa was well tolerated in the current study,
and almost all the AEs reported appeared to be related to
chemotherapy.Althoughtheratesoftreatment-emergent
venous thrombosis were found to be similar in the two
treatment arms, serious thrombovascular events were
more frequent in the epoetin alfa group. A higher inci-
dence of thrombovascular events is considered a known
and labeled event in cancer patients receiving ESAs. Al-
though our study was neither designed nor powered to
detect differences in survival, it is important to note that
the survival curves were overlapping at 12 months.
However, some investigational clinical studies have
suggested that ESA therapy might be harmful in certain
groupsofpatientswithcancer[12–14].Oneofthesestudies
was the Breast Cancer Erythropoietin Survival Trial. That
large clinical trial enrolled 939 patients with metastatic
breastcancerreceivingfirst-linechemotherapy.Thosewith
hemoglobin concentrations 13 g/dl were treated with ei-
ther epoetin alfa or placebo for 12 months [13]. The study
was stopped early because of poorer overall survival in the
epoetinalfaarmthanintheplaceboarmoverthe12months
(70% versus 76%; p  .01). However, most of the survival
difference occurred during the first 4 months (epoetin alfa,
41 deaths; placebo, 16 deaths); the numbers of deaths over
the subsequent period were similar (epoetin alfa, 97; pla-
cebo, 95). Furthermore, other studies evaluating the effect
of ESAs in patients with breast cancer have reported com-
parable findings on survival and/or tumor progression in
ESA-treated patients versus standard of care. In a multi-
center phase III trial evaluating the effect of epoetin alfa on
anemiaandsurvival,658patientswithbreastcancerreceiv-
ing a dose-dense epirubicin–cyclophosphamide–paclitaxel
regimen (ETC) [15] were randomized to receive epoetin
alfa (n  333) or no epoetin alfa. Anemia was significantly
less prevalent in the ETC–epoetin alfa arm (p  .0001). At
a median follow-up of 62 months, no difference between
the ETC-only arm and the ETC–epoetin alfa arm was ob-
served in the 5-year disease-free survival rate (71% versus
72%, respectively; p  .86) and in the overall survival rate
(83% versus 81%, respectively; p  .89) [15]. Similar re-
Table 3. Baseline clinical stage and age by treatment
group (intent-to-treat population)
n of patients (%) in treatment group
Epoetin alfa
(n  110)
Best standard
care (n  113)
n (%) n (%)
Clinical stage
I 13 (11.8%) 17 (15.1%)
II 33 (30.0%) 31 (27.4%)
III 10 (9.1%) 13 (11.5%)
IV 51 (46.4%) 48 (42.5%)
Missing 3 (2.7%) 4 (3.5%)
Age
50 yrs 43 (39.1%) 43 (38.0%)
50 yrs 67 (60.9%) 70 (61.9%)
Table 4. Association between epoetin alfa and best
standard care (BSC) group controlled by baseline factors
for survival (intent-to-treat population)
Baseline variable/
contrast
Hazard
ratio
95% confidence
interval p-value
Epoetin alfa versus
control (BSC)
1.12 (0.600–2.102) .7161
Cancer diagnosis
clinical stage I–III
versus stage IV
0.14 (0.057–0.329) .001
Age 50 yrs versus
50 yrs
3.11 (1.293–7.459) .0113
Table 5. Adverse events reported by 5% of patients in
either treatment group (safety population, n  220)
Adverse event
Epoetin alfa
(n  109),
n (%)
Best standard
care (n  111),
n (%)
Any adverse event 99 (90.8) 98 (88.3)
Gastric/duodenal disorder 38 (34.9) 25 (22.5)
WBC decreased 32 (29.4) 31 (27.9)
Skin dysfunction 14 (12.8) 16 (14.4)
Bone/joint disorder, ns 14 (12.8) 7 (6.3)
Oropharyngeal disorder 13 (11.9) 11 (9.9)
Small/large bowel disorder 12 (11.0) 19 (17.1)
Pulmonary, ns/general 12 (11.0) 17 (15.3)
Mucous membrane disorder 9 (8.3) 15 (13.5)
RBC decreased 9 (8.3) 9 (8.1)
Abdominal disorder, ns 9 (8.3) 13 (11.7)
Chest disorder, ns 8 (7.3) 8 (7.2)
Anxiety/neurosis 6 (5.5) 3 (2.7)
Head disorder, ns 6 (5.5) 3 (2.7)
Eye, local 6 (5.5) 7 (6.3)
Thrombosis, venous 8 (7.3) 7 (6.3)
Motor neuron/peripheral
motor
3 (2.8) 6 (5.4)
Sensory disorder 5 (4.6) 6 (5.4)
Abbreviation: ns, nonspecific.
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with breast cancer [16, 17]. A randomized, double-blind,
multicenter study (Preoperative Epirubicin-Paclitaxel-
Aranesp, PREPARE) evaluated the effects of darbepoetin
in combination with chemotherapy in patients with breast
cancer (n  773); no difference in tumor response or pro-
gression was observed in those who received darbepoetin
(n  356) versus those who did not (n  377), although the
survival duration was shorter and there were more relapses
in the group of patients treated with darbepoetin [17]. A
randomized, open-label study evaluated the effects of epo-
etin beta on overall survival in patients with metastatic
breast cancer receiving chemotherapy (Breast Cancer Ane-
mia and the Value of Erythropoietin, BRAVE, n  463)
[16]. At 18 months of follow-up, no significant difference
wasdetectedinoverallsurvival(hazardratio,1.07;95%CI,
0.87–1.33) or progression-free survival (hazard ratio, 1.07;
95% CI, 0.89–1.30) between the epoetin beta group (n 
231)andthecontrolgroup(n232).However,theauthors
cautionedthat,becauseofthedesignofthestudy,clinically
important differences in survival could not be excluded
with absolute certainty.
CONCLUSION
Inconclusion,theresultsofthisstudydemonstratethatepo-
etin alfa is generally well tolerated and can protect against
anemia and attenuate deteriorations in anemia-related
PROswhenadministeredearlyduringthecourseofchemo-
therapy to patients with mild to moderate anemia. In partic-
ular, this early intervention allows patients to maintain a
positive sense of well-being and ability to function, to ex-
perience less fatigue during chemotherapy, potentially
avoidingthedeteriorationassociatedwithmoresevereane-
mia, and to maintain productivity [18, 19].
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